HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $30 Price Target

First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Inc

TRAX

0.00

HC Wainwright & Co. analyst Emily Bodnar reiterates First Tracks (NASDAQ: TRAX) with a Buy and maintains $30 price target.